Tag: Ibrutinib (Imbruvica)

By Posted on Posted in New Drug Approval, Targeted Therapy, Thasso Post, Theragenomics Tagged with , , ,

July 28, 2014 – The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor …

The use of Ibrutinib [Imbruvica] expanded to the treatment of chronic lymphocytic leukaemia Read more »

By Posted on Posted in New Drug Approval, Targeted Therapy, Thasso Post, Theragenomics Tagged with , , , , , , , , ,

July 23, 2014 – The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. Zydelig is being granted traditional approval to treat patients whose chronic lymphocytic leukemia (CLL) has returned (relapsed). …

Idelalisib (Zydelig) for three types of blood cancers approved Read more »